Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Circulating IL-35 in pancreatic ductal adenocarcinoma patients.

Jin P, Ren H, Sun W, Xin W, Zhang H, Hao J.

Hum Immunol. 2014 Jan;75(1):29-33. doi: 10.1016/j.humimm.2013.09.018. Epub 2013 Oct 11.

PMID:
24121041
2.

Decreased IL-35 levels in patients with immune thrombocytopenia.

Yang Y, Xuan M, Zhang X, Zhang D, Fu R, Zhou F, Ma L, Li H, Xue F, Zhang L, Yang R.

Hum Immunol. 2014 Aug;75(8):909-13. doi: 10.1016/j.humimm.2014.06.019. Epub 2014 Jun 30.

PMID:
24994465
3.

Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells.

Qu D, Johnson J, Chandrakesan P, Weygant N, May R, Aiello N, Rhim A, Zhao L, Zheng W, Lightfoot S, Pant S, Irvan J, Postier R, Hocker J, Hanas JS, Ali N, Sureban SM, An G, Schlosser MJ, Stanger B, Houchen CW.

PLoS One. 2015 Feb 27;10(2):e0118933. doi: 10.1371/journal.pone.0118933. eCollection 2015.

4.

Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.

Jin A, Xu Y, Liu S, Jin T, Li Z, Jin H, Lin L, Lin Z.

Exp Mol Pathol. 2014 Feb;96(1):54-60. doi: 10.1016/j.yexmp.2013.11.003. Epub 2013 Nov 18.

PMID:
24263054
5.

Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.

Weng S, Wang H, Chen W, Katz MH, Chatterjee D, Lee JE, Pisters PW, Gomez HF, Abbruzzese JL, Fleming JB, Wang H.

Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1336-43. doi: 10.1158/1055-9965.EPI-12-0223. Epub 2012 Jun 4.

6.

High Expression of Human Leukocyte Antigen-G is Associated with a Poor Prognosis in Patients with PDAC.

Xu YF, Lu Y, Cheng H, Jiang J, Xu J, Long J, Liu L, Ni Q, Liu C, Yu XJ.

Curr Mol Med. 2015;15(4):360-7.

PMID:
25829020
7.

[Expression and clinical significance of Tspan 1 and Integrin α6 in human pancreatic ductal adenocarcinoma].

Shi G, Dong M, Sheng W, Zhou J, Yu D, Sun W.

Zhonghua Wai Ke Za Zhi. 2014 Oct;52(10):781-6. Chinese.

PMID:
25573220
8.

High expression of interleukin-22 and its receptor predicts poor prognosis in pancreatic ductal adenocarcinoma.

Wen Z, Liao Q, Zhao J, Hu Y, You L, Lu Z, Jia C, Wei Y, Zhao Y.

Ann Surg Oncol. 2014 Jan;21(1):125-32. doi: 10.1245/s10434-013-3322-x. Epub 2013 Oct 17.

PMID:
24132627
9.

Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer.

Abue M, Yokoyama M, Shibuya R, Tamai K, Yamaguchi K, Sato I, Tanaka N, Hamada S, Shimosegawa T, Sugamura K, Satoh K.

Int J Oncol. 2015 Feb;46(2):539-47. doi: 10.3892/ijo.2014.2743. Epub 2014 Nov 10.

10.

An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma.

Dima SO, Tanase C, Albulescu R, Herlea V, Chivu-Economescu M, Purnichescu-Purtan R, Dumitrascu T, Duda DG, Popescu I.

Pancreas. 2012 Oct;41(7):1001-7. doi: 10.1097/MPA.0b013e3182546e13.

PMID:
22722257
11.

Increased B cell-activating factor promotes tumor invasion and metastasis in human pancreatic cancer.

Koizumi M, Hiasa Y, Kumagi T, Yamanishi H, Azemoto N, Kobata T, Matsuura B, Abe M, Onji M.

PLoS One. 2013 Aug 6;8(8):e71367. doi: 10.1371/journal.pone.0071367. Print 2013.

12.

Intra-tumoral IFN-γ-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer.

Niccolai E, Taddei A, Ricci F, Rolla S, D'Elios MM, Benagiano M, Bechi P, Bencini L, Ringressi MN, Pini A, Castiglione F, Giordano D, Satolli MA, Coratti A, Cianchi F, Bani D, Prisco D, Novelli F, Amedei A.

Clin Sci (Lond). 2016 Feb;130(4):247-58. doi: 10.1042/CS20150437. Epub 2015 Nov 20.

PMID:
26590104
13.

A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1α in pancreatic ductal adenocarcinoma.

Sun YW, Chen YF, Li J, Huo YM, Liu DJ, Hua R, Zhang JF, Liu W, Yang JY, Fu XL, Yan T, Hong J, Cao H.

Br J Cancer. 2014 Nov 25;111(11):2131-41. doi: 10.1038/bjc.2014.520. Epub 2014 Oct 14.

14.

MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis.

Kadera BE, Li L, Toste PA, Wu N, Adams C, Dawson DW, Donahue TR.

PLoS One. 2013 Aug 22;8(8):e71978. doi: 10.1371/journal.pone.0071978. eCollection 2013.

15.

Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.

Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H.

J Hematol Oncol. 2012 Apr 4;5:15. doi: 10.1186/1756-8722-5-15.

16.

Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.

Carlsen AL, Joergensen MT, Knudsen S, de Muckadell OB, Heegaard NH.

Pancreas. 2013 Oct;42(7):1107-13. doi: 10.1097/MPA.0b013e318296bb34.

PMID:
24048453
18.

Levels of Alternatively Spliced Tissue Factor in the Plasma of Patients with Pancreatic Cancer May Help Predict Aggressive Tumor Phenotype.

Unruh D, Sagin F, Adam M, Van Dreden P, Woodhams BJ, Hart K, Lindsell CJ, Ahmad SA, Bogdanov VY.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1206-11. doi: 10.1245/s10434-015-4592-2. Epub 2015 May 12.

PMID:
25963480
19.

Circulating tumor cells found in patients with localized and advanced pancreatic cancer.

Kulemann B, Pitman MB, Liss AS, Valsangkar N, Fernández-Del Castillo C, Lillemoe KD, Hoeppner J, Mino-Kenudson M, Warshaw AL, Thayer SP.

Pancreas. 2015 May;44(4):547-50. doi: 10.1097/MPA.0000000000000324.

PMID:
25822154
20.

IL-8-Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients.

Fang Y, Saiyin H, Zhao X, Wu Y, Han X, Lou W.

Pancreas. 2016 May-Jun;45(5):671-8. doi: 10.1097/MPA.0000000000000520.

PMID:
26495785

Supplemental Content

Support Center